Equillium to Participate in the 38th Annual Roth Conference

Rhea-AI Summary

Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on March 23, 2026 at 8:30am PT. The company said members of management will also be available for investor meetings with conference registrants.

This presentation offers investors direct access to management and updates on corporate strategy and development plans.

News Market Reaction – EQ

-0.93%

2 alerts

-0.93% News Effect

-$1M Valuation Impact

$136M Market Cap

0.1x Rel. Volume

On the day this news was published, EQ declined 0.93%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $136M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 38th Conference date: March 23, 2026 Session time: 8:30am PT

3 metrics

Conference edition 38th 38th Annual Roth Conference for Growth Companies

Conference date March 23, 2026 Scheduled fireside chat date

Session time 8:30am PT Time of Equillium fireside chat

Market Reality Check

Price: $2.13 Vol: Volume 448,515 is about 0...

normal vol

$2.13 Last Close

Volume Volume 448,515 is about 0.74x the 20-day average of 606,804, indicating quieter trading ahead of the conference. normal

Technical Shares at $2.15 are trading above the 200-day MA of $1.17, despite a -7.33% move over the last 24 hours.

Peers on Argus

EQ fell 7.33% while peers showed mixed moves: BMEA (-3.94%), FATE (-4.24%), AVTX...

1 Up

EQ fell 7.33% while peers showed mixed moves: BMEA (-3.94%), FATE (-4.24%), AVTX (-3.33%) down, but CRBP (+0.73%) and ZURA (+2.55%) up. Only FATE appeared on the momentum scanner, confirming stock-specific factors rather than a broad sector swing.

Common Catalyst Multiple biotech peers, including EQ and CRBP, announced participation in investor conferences, highlighting an active conference calendar rather than a unified sector catalyst.

Historical Context

5 past events · Latest: Mar 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 13	PIPE financing	Positive	+19.3%	Announced approximately $35M PIPE financing with RA Capital to extend cash runway.
Feb 25	Conference participation	Neutral	-4.7%	Planned fireside chat and investor meetings at Leerink Partners healthcare conference.
Feb 02	Inducement grants	Neutral	+0.0%	Reported stock option inducement grants to new employees under 2024 Inducement Plan.
Nov 20	Investor conferences	Neutral	-5.0%	Planned participation in December 2025 Piper Sandler and Evercore ISI healthcare conferences.
Nov 13	Earnings and financing	Positive	+23.8%	Q3 2025 results plus private placement of up to $50M and EQ504 development plans.

Pattern Detected

EQ often reacted positively to financing and earnings updates, while conference participation headlines have sometimes coincided with modest share price declines.

Recent Company History

Over the past six months, Equillium has combined financing activity with clinical and corporate planning. On Nov 13, 2025, Q3 2025 results and a private placement of up to $50.0M coincided with a 23.81% gain. A $35M PIPE financing on Mar 13, 2026 saw shares rise 19.32%. In contrast, multiple conference participation announcements in Nov 2025 and Feb 2026 were followed by single‑digit percentage declines, suggesting routine investor events have not been primary upside drivers.

Regulatory & Risk Context

Active S-3 Shelf · $250,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-13

$250,000,000 registered capacity

Equillium has an effective Form S-3 shelf filed on Nov 13, 2025 to offer up to $250,000,000 in various securities, including an at-the-market program of up to $75,000,000 of common stock through LifeSci Capital, providing capacity for future capital raises.

Market Pulse Summary

This announcement highlights Equillium’s participation in the 38th Annual Roth Conference on March 2...

Analysis

This announcement highlights Equillium’s participation in the 38th Annual Roth Conference on March 23, 2026, including a fireside chat and investor meetings. Similar appearances at healthcare and investor conferences have been a recurring part of the company’s outreach. In parallel, Equillium maintains a Form S-3 shelf capacity of up to $250,000,000, which, together with prior financings, frames its flexibility to fund programs like EQ504. Investors may watch for any follow‑up disclosures or presentations linked to this event.

Key Terms

autoimmune, inflammatory disorders

2 terms

autoimmune medical

"developing novel therapies to treat severe autoimmune and inflammatory disorders"

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

inflammatory disorders medical

"developing novel therapies to treat severe autoimmune and inflammatory disorders"

Inflammatory disorders are conditions in which the body's defense system becomes overactive or misdirected, causing redness, swelling, pain or long-term tissue damage in organs, joints or skin. For investors, these conditions matter because they drive demand for drugs, tests and therapies; successful treatments can create large, recurring revenue streams, while failed trials, regulatory hurdles or competing therapies can affect a company’s value much like a product winning or losing a major market battle.

AI-generated analysis. Not financial advice.

LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38^th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT.

Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

About Equillium
Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

For more information, visit www.equilliumbio.com.

Investor Contact 
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

FAQ

When will Equillium (EQ) present at the 38th Annual Roth Conference?

Equillium will present on March 23, 2026 at 8:30am PT. According to the company, this is a scheduled fireside chat during the conference for growth companies, offering a dedicated management presentation and investor engagement opportunities.

Where will Equillium (EQ) management be available for investor meetings at the Roth Conference?

Management will be available to meet with registered investors attending the conference. According to the company, meetings are limited to conference registrants and provide one-on-one opportunities to discuss corporate strategy and programs.

What is the purpose of Equillium's (EQ) fireside chat at the Roth Conference?

The fireside chat aims to present corporate updates and engage investors directly. According to the company, management will use the session to discuss strategy, progress on development programs, and to answer investor questions.

Who from Equillium (EQ) will participate in the Roth Conference fireside chat?

Members of Equillium's management team will participate in the fireside chat. According to the company, multiple management representatives are scheduled to appear and to be available for investor meetings at the event.

How can investors access Equillium's (EQ) Roth Conference presentation or meetings?

Access is available to investors registered for the Roth Conference. According to the company, registered attendees may attend the fireside chat and request meetings with available members of management during the conference.